Background-Vasculogenic cell-based therapy combined with tissue engineering is a promising revascularization approach targeted at patients with advanced coronary artery disease, many of whom exhibit myocardial hibernation. However, to date, no experimental data have been available in this context; we therefore examined the biopolymer-supported delivery of circulating angiogenic cells using a clinically relevant swine model of hibernating myocardium. Methods and Results-Twenty-five swine underwent placement of an ameroid constrictor on the left circumflex artery.
M yocardial hibernation is a common clinical condition affecting patients with advanced coronary artery disease, 1 for whom cell-based therapies are targeted. In hibernation, repetitive episodes of ischemia and reperfusion lead to metabolic and functional changes in cardiomyocytes, ultimately impairing left ventricular (LV) function. Current therapies such as coronary artery bypass grafting or percutaneous coronary intervention are well established but not suitable for all patients; in previous clinical research from our group, more than one third of patients referred for revascularization did not undergo intervention because of unsuitable vessel anatomy, comorbidities, or other reasons. 1 These patients are at high risk of cardiac events, and novel approaches such as cell-based vasculogenic therapy could provide them with an alternative form of therapy.
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Circulating angiogenic cells (CACs) constitute a heterogeneous population of peripheral blood-derived fibronectincultured cells. Although what defines their phenotype is still debated, 2 they were shown to uptake acetylated low-density lipoprotein, bind Ulex europaeus agglutinin-1 lectin, and express the pan-leukocyte marker CD45. They can also stain positive for monocyte/macrophage (CD14, CD11b/Mac-1, and CD11c) and endothelial (vascular endothelial growth factor receptor 2, von Willebrand factor, vascular endothelialcadherin, and CD31) markers. [3] [4] [5] Transplanted cells likely contribute to neovascularization through a paracrine mechanism by secreting and recruiting cardioprotective or proangiogenic growth factors. 6, 7 The revascularization potential of CACs has been confirmed in animal models of ischemia and infarction. [8] [9] [10] [11] However, the benefits of cell transplantation, using CACs or other cell types, have not been investigated in the setting of myocardial hibernation, which is frequently encountered in patients with advanced coronary artery disease. 1 Furthermore, the enhancement of such therapies with biomaterials remains poorly studied in large animal models.
We and others have previously showed that biomaterial scaffolds, such as collagen-based polymer matrices, are attractive for regenerative medicine and may reduce relocation of transplanted cells, 12 improve LV function, 13 and improve vascular density. 14 In the present study, we induced and validated a preclinical model of myocardial ischemia and hibernation and used it to investigate the benefits of biopolymer-supported CAC delivery in this clinically relevant setting.
Methods

General Experimental Sequence and Animal Protocol
All experimental procedures were performed in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. The general experimental sequence is shown in Figure 1 . Briefly, a total of 32 female Yorkshire pigs (8-10 kg at first surgery) underwent a small left thoracotomy for placement of an ameroid constrictor (1.5-2.0 mm; Research Instruments, Escondido, CA) around the proximal left circumflex artery (LCx; Figure I in the online-only Data Supplement). Two weeks later, pigs underwent (1) blood harvest for CAC isolation, (2) transthoracic echocardiography, (3) rest 13 N-ammonia (NH 3 ) positron emission tomography (PET), (4) dipyridamole-induced stress 13 N-NH 3 PET (see stress protocol details in the online-only Data Supplement), and (5) rest 18 F-fluorodeoxyglucose (FDG) PET. The following week, the swine underwent a second thoracotomy and the lateral wall of the heart was exposed to allow direct intramyocardial delivery of treatment; animals were randomized to receive injections of PBS alone (control; n=10), CACs (n=8), or the combination of CACs+collagenbased matrix (n=7). Twelve 0.25 mL injections (total volume of 3 mL) were made in the hibernating portion of the lateral wall after the hibernating area was determined by PET and reviewed before injections. In the 2 groups that received cells, a mean of 32.7±3.9×10 6 cells was used.
At week 6, animals underwent follow-up PET and echocardiography. Rest and dipyridamole-induced stress myocardial blood flow (MBF; was also determined at 3 and 7 weeks by using isotope-labeled microspheres (ILMs). At week 7, animals were euthanized and hearts were harvested and sliced for microsphere and immunohistochemical analyses, as described in the online-only Data Supplement.
CAC Isolation and Culture
Approximately 60 mL of autologous blood was used to isolate and culture CACs. Cultures were supplemented with endothelial basal media with EGM-2-MV SingleQuots (Clonetics, Guelph, Canada), and adherent cells were used for injection on day 6. Cells were resuspended in 3 mL of PBS or collagen-based matrix. Details of CAC isolation and culture are provided in the online-only Data Supplement.
Collagen Matrix Preparation
Collagen-based matrices were prepared on ice by blending type I rat tail collagen (0.4% wt/vol; BD Bioscience, Oakville, Canada) with chondroitin sulfate C (40% wt/vol; Wako Chemicals, Osaka, Japan), as described previously. 15 Briefly, components were mixed on ice and cross-linked with glutaraldehyde (1.5%). Residual aldehyde groups were inactivated by the addition of glycine (20%). The pH was adjusted to 7.2 to 7.5, and cells were added to the matrix before injection. This preparation was liquid at 4°C and solidified at 37°C.
Echocardiography
Rest transthoracic echocardiography images were acquired with a Phillips Sonos 5500 ultrasound machine and analyzed with Xcelera (Philips Healthcare, Andover, MA). Simpson's LV ejection fraction (LVEF) was determined on 2-dimensional (2D) acquisitions. Using either a 2-or 4-chamber view, regional wall motion was evaluated by visual analysis of systolic thickening and reported according to the 16-segment model recommended by the American Society of Echocardiography. 16 A normal or hyperkinetic segment was assigned a score of 1; hypokinetic, 2; akinetic, 3; and dyskinetic, 4. Wall motion score index (WMSI) was calculated by dividing the total wall motion score for each animal by the number of segments visualized.
Positron Emission Tomography
Imaging Sequence
After an overnight fast, pigs were anesthetized, intubated, mechanically ventilated, and placed in a right lateral position on the bed in one of the following PET scanners: ECAT ART (Siemens), Discovery RX or 690 (General Electric). A 12-lead ECG was used to monitor the heart. After a low-dose 137 Cs transmission 17 or x-ray computed tomography 18 scan for attenuation correction, each animal underwent rest and dipyridamole stress (0.56 mg/kg) imaging with 13 N-NH 3 (20 minutes) 19 and rest imaging with 18 F-FDG (60 minutes) 20 to obtain regional estimates of MBF (mL·min −1 ·g −1 ) and glucose uptake (MBq/mL), respectively. Each acquisition was dynamic and was separated by a 40-minute period to allow decay of 13 N-NH 3 activity. For each scan, radiotracers were injected via an ear catheter using a syringe pump (infusion time, 30 s; volume, 10 mL), and all activity residuals were flushed from the intravenous line at the end of infusion using an additional 10 mL of saline. The total activity injected was ≈200 to 550 MBq for ammonia scans and 150 to 300 MBq for FDG scans (dose by weight; ≈15 kg at scan 1, and 40 kg at scan 2). To increase myocardial glucose uptake and image quality on the FDG scans, a euglycemic hyperinsulinemic clamp was used 21 
Image Processing
Images were processed using FlowQuant 22 (Ottawa, Canada). For MBF quantification, time activity curves were derived from sampling regions of interest in the myocardium and LV cavity, base, and atrium blood pools. The rates of 13 N-NH 3 uptake at rest and stress were quantified using a 1-compartment model. 23 Absolute MBF (mL·min −1 ·g −1 ) was quantified and reported according to a standard 17-segment model. Mismatch analyses were performed by comparing relative NH 3 and FDG uptake at rest, as previously described. 24 Briefly, the LV was divided in 460 sectors, and each sector was expressed as a percent of the maximum tracer uptake, defining perfusion and FDG scores. Mismatch (hibernating myocardium) was defined as a segment with reduced perfusion with FDG score greater than the perfusion. A match defect representing scar tissue was defined in regions where FDG score was less than or equal to perfusion. 25 Mismatch and match scores were also reported following a 17-segment model.
PET analyses did not include explicit coregistration with coronary anatomy, but all images were analyzed in a standard myocardial orientation, with the interventricular septum centered on segment 14. To report regional analyses, we used the standard combination of segments corresponding to each coronary artery territories from the 17-segment model 26 (excluding the apex from the left anterior descending [LAD] territory), therefore assuming similar coronary anatomy between animals.
MBF Determination With Microspheres
MBF was assessed at surgeries 2 (week 3) and 3 (week 7) using 15 µm ILMs (BioPAL, Worcester, MA). ILMs of different isotopic mass were used for each measurement. MBF was calculated based on the number of ILMs in myocardial tissue segments. The detailed protocols used to slice the heart ( Figure III 
Immunohistochemistry Analyses
Slides were stained with α-smooth muscle actin to detect arterioles (see the detailed protocol in the online-only Data Supplement).
Statistical Analyses
The study animals were randomly selected to receive 1 of the 2 treatments or control injections. All analyses were performed by blinded observers, and study groups were revealed only after completion of quantitative determinations.
Results are presented as mean±SE. Statistical analyses were performed by using Sigma Stat (Ashburn, VA). Paired Student t tests were used to compare values between the affected and remote regions of the heart, and between baseline and follow-up. Comparisons between groups were done by using a 1-way ANOVA, and 2-tailed Student t tests, assuming equal variances. Bonferroni correction procedures were not used. Significance is reported for P<0.05.
Results
Three pigs died during the first surgery, 1 died at induction of the first anesthesia, 2 died during the first PET stress scan, and 1 animal from the cell group died during the second stress scan. No autopsy was performed on these animals considering that the incidence of sudden cardiac deaths attributable to fibrillation or massive myocardial infarction can reach up to 30%, particularly during the period of ameroid closure. [27] [28] [29] All remaining pigs (25 in total) completed the study protocol. Unless otherwise specified, findings are reported for the LCx territory. A summary of all outcome measures is provided in Table 1 .
Ameroid Constrictor Model Induced Myocardial Ischemia, Hibernation, and Wall Motion Abnormalities
Two and 3 weeks after ameroid placement, both PET and microsphere analyses showed a marked reduction in MBF at rest, MBF at stress, and myocardial flow reserve (MFR) in the LCx region-at-risk, compared with the left anterior Table 2 ). Mean mismatch (9.07±1.81 versus 3.24±1.14; P<0.001) and match (7.24±1.27 versus 3.81±1.05; P=0.002) scores were higher in the LCx than in the LAD region ( Figure 2E and 2F ). Wall motion abnormalities were observed in the lateral and inferoposterior walls, consistent with the LCx region-at-risk, and the mean WMSI was 1.29±0.04.
CACs Delivered in a Collagen-Based Matrix Increased MBF During Stress and Positively Altered MFR on PET
At baseline, there was no difference between groups in rest MBF (P=0.98), stress MBF (P=0.59), and MFR (P=0.41). Three weeks after treatment, rest MBF remained unchanged in all groups, whereas stress MBF increased in the cells+matrix group only (0.95±0.15 to 1.24±0.12 mL·min −1 ·g −1 ; P=0.04; Figure 3A ). MFR did not change in the control and cells groups (P=0.40 and P=0.66, respectively), whereas there was a strong trend toward an improvement when cells were delivered within the matrix (from 1.08±0.14 to 1.47±0.12; P=0.05).
The highest increase in stress MBF was in the cells+matrix group (+53.89±31.10%), which was significantly higher than PBS and cells alone (−1.13±23.3%; P=0.02). Similarly, the increase in MFR was greatest in the cells+matrix group (+52.42±25.06%), compared with PBS and cells alone (+2.45±24.15%; P=0.04).
CACs Delivered in a Collagen-Based Matrix Increased MBF During Stress Measured by Microspheres
There was no difference in rest MBF (P=0.14), stress MBF (P=0.86), and MFR (P=0.56) between the groups at baseline. Under resting conditions, MBF remained unchanged in all treatment groups between baseline and follow-up. Stress MBF increased from 0.80±0.14 to 1.92±0.39 mL·min −1 ·g −1 (P=0.02) in the cells+matrix group, showed a trend toward increasing from 0.72±0.15 to 1.14±0.23 (P=0.07) in the cells group, whereas it did not change in a statistically significant manner in the PBS group (P=0.10; Figure 3B ).
CACs Delivered in a Collagen-Based Matrix Increased Myocardial Viability on PET
Mismatch (P=0.51) and match scores (P=0.84) did not differ between groups at baseline. At follow-up, mismatch scores significantly decreased only in the animals that were treated with the combination of cells+matrix (P=0.006; Figure 4 ). There was no difference in match scores between baseline and follow-up in any of the groups. In the control group, 2 pigs had a global reduction in mismatch paralleled by a global increase in match, suggesting progression from viable to scar tissue. In a subanalysis of segments with the highest mismatch at baseline (see segment selection in the online-only Data Supplement), mismatch scores at follow-up decreased in the cells+matrix (0.19±0.09) and cells (1.06±0.7) groups compared with controls (9.38±2.73; P=0.02 and P=0.04, respectively), and match scores only significantly decreased in the cells+matrix group (P=0.007).
CACs Delivered in a Collagen Matrix Improved Regional Wall Motion and Positively Impacted LVEF
At baseline, LVEF trended to be higher in the control group compared with the 2 other groups (P=0.06; Table 1 ), and there was no difference in regional wall motion score (P=0.16) between groups. Regional WMSI improved from 1.41±0.06 to 1.27±0.06 (P=0.049) when cells were delivered within the collagen matrix. When cells were delivered alone, there was a trend toward an improvement in WMSI (baseline WMSI=1.24±0.06; follow-up WMSI=1.17±0.04; P=0.08), and when only PBS was delivered, there were no changes in WMSI (baseline WMSI=1.22±0.08; follow-up WMSI=1.17±0.09; P=0. 22) .
From baseline LVEF, the cells+matrix group showed a +16.29±6.7% increase in LVEF, which was higher than the variation in the PBS group (−2.76±2.7%; P=0.02) but not different from the changes in the cell group (+11.45±9.14%; P=0.68). There was no difference between the cells and the PBS groups (P=0.14; Figure 5 ).
CACs Delivered in a Collagen-Based Matrix Increased Arteriolar Density
Cells+matrix-treated hearts (n=5) demonstrated greater arteriole number (10.9±1.3 arterioles per field of view) in the LCx territory compared with cells-treated animals (n=6; 6.3±0.9; P=0.01) and controls (n=8; 4.3±0.6; P<0.001; Figure 6 ). Similar results were found in the LAD territory where arterioles were more abundant in the cells+matrix-treated animals (10.9±1.55 arterioles per field of view) compared with both the cells-(5.7±0.7; P=0.004) and the PBS-treated animals (3.8±0.8; P<0.001). In the LCx, there was a trend toward a higher mean arteriole number in the cells group compared with PBS group (P=0.08). There was a strong positive correlation between follow-up microsphere MBF at stress and the number of arterioles in the LCx (r=0.7; P=0.008) and LAD (r=0.66; P=0.01) territories. 
Discussion
To our knowledge, this study is the first to demonstrate, in a preclinical model of hibernating myocardium, that the vasculogenic potential of transplanted CACs is enhanced when cells are delivered in a biomaterial. In our opinion, this is important because myocardial hibernation is present in up to 50% of patients with coronary artery disease 30 and more than one third of these may not get appropriate treatment. 1 Consequently, the applicability of cell-based therapies is particularly relevant in this population, as early cell and biomaterial delivery may promote revascularization before irreversible damage to the myocardium occurs, in a context where currently available therapies may commonly not be feasible.
The combination of autologous angiogenic cells and naturally occurring extracellular matrix components successfully improved stress MBF and MFR in our study. Improved MFR suggests an increased response capacity to higher oxygen demands by recruitment or generation of new vasculature. These animals also displayed lower amounts of mismatch and match, suggesting a better recovery of myocardial viability following matrix delivery of CACs. Histological findings were also supportive of the enhanced benefits conferred by the matrix because cells delivered in the matrix doubled the number of arterioles in the myocardium. In the presence of myocardial hibernation, enhanced vasculogenesis may constitute an important mechanism of improved LV function in animals or patients undergoing successful cell therapy. In this study, vasculogenic improvements were paralleled by an improvement in wall motion and a strong trend toward an improvement in LVEF. This occurred despite the relatively small area of hibernation, the early follow-up time points, and the physiological and metabolic rather than functional emphasis of the experiments. A mixture of hibernating and nonvascularized scar tissue partly explains the persistence of low LCx resting flow at follow-up in all groups. In addition, it is likely that in the PBS and cell groups, supply of resting MBF required maximum capillary recruitment, whereas it was not exhausted in the cells+matrix group which allowed additional recruitment with higher MBF at stress.
Because the region of ischemia may not encompass all the LCx territory segments in every animal, we conducted a subanalysis using 2 segments with the lowest stress MBF at baseline. The effects of treatment were of higher magnitude and significance compared with the whole LCx region because the results were less diluted as a consequence ( Table I in the online-only Data Supplement). For viability, the 2-segment analysis showed a significant decrease in mismatch in every group, with the most significant decrease observed in the cells+matrix group.
Although detailed comparisons of absolute microsphere and PET MBF were beyond the scope of this study, both modalities confirmed the establishment of myocardial ischemia after 2 weeks and supported the enhanced benefits of cell delivery within the matrix. In addition, a strong positive correlation between stress MBF and arteriole density validated those findings, although evaluation of capillary density was not performed. In a sample of 2 animals, we also visually confirmed a good geographic correspondence of ischemic regions between PET and microsphere-measured stress MBF, where microsphere MBF was measured in 41 samples covering the entire LV and represented in a polar map ( Figure IV in the online-only Data Supplement). This subanalysis also confirmed that the segments selected for histological analyses were representative of the area at risk as defined on the stress PET MBF images.
Notably, the transplantation of cells alone was not successful in increasing MBF, reducing match scores and significantly increasing the number of arterioles compared with controls. Similar findings were reported by Chen et al, 31 who were unsuccessful at improving the ischemic pig heart with CAC transplantation. In the majority of studies using cultured mononuclear cells from bone marrow or peripheral blood origin and conducted in chronic ischemic models, the number of cells injected range from 2.5 million 31 to 17 million, 32 and the observed functional improvements vary. A dosing study in ischemic pig myocardium showed a dose-dependent effect of bone marrow mononuclear cells on capillary density and suggested that the local number of cells was a better predictor of increased capillary density and reduced fibrosis than the total number of cells injected. Segments with >20 million cells had the highest capillary density and the lowest amount of fibrosis. 33 We can hypothesize that cells delivered within the matrix may have been better protected against the adverse effects of syringe needle flow. The viability of a variety of stem and progenitor cells during syringe needle flow was shown to be decreased when cells were delivered in PBS compared with the use of a cross-linked alginate hydrogel. 34 In addition, the low engraftment and survival 35 of transplanted cells limit their benefits. In this regard, we have previously demonstrated by tracking cells with PET and by histology that our collagen-based matrix can improve cell retention and prevent excessive relocation of transplanted cells to nontarget tissues, 36 in addition to improving capillary density. 14 We also previously showed that CACs exposed to the matrix demonstrated higher levels of phosphorylated Akt (PI3K/Akt pathway) and increased survival under hypoxia. 15 Based on the ability of the collagen matrix to modulate the therapeutic phenotype and function of CACs, it may have induced similar effects in the pig model of this study. The increased retention and viability of cells within the matrix may also have provided more prolonged paracrine effects because transplanted cells secrete proangiogenic factors 37 and upregulate host-derived cytokine secretion. 7 In our study, cells were delivered intramyocardially during the second thoracotomy. Clinically, intramyocardial cell transplantation can be done surgically, and newer techniques such as 3D electromechanical mapping (3D NOGA EMM) can evaluate ischemia less invasively and allow for catheter-based transendocardial delivery of cells. 38 This approach has been used in large animals studies 11, 32, 39 and in small clinical trials. [40] [41] [42] [43] In line with the higher cell retention rates when delivered intramyocardially, a recent meta-analysis demonstrated that LVEF was improved by 8.4% when bone marrow progenitor cells were delivered directly to the myocardium. 44 In this study, we also validated a relevant preclinical model of myocardial hibernation. MBF was evaluated with PET and microspheres, whereas viability was investigated with FDG PET, 45 the gold standard for viability imaging. We systematically compared the affected LCx territory with the nonaffected LAD region. After 2 and 3 weeks of ameroid placement, rest and stress MBF were markedly reduced in affected regions, leading to impaired MFR. Most areas with impaired MBF were viable as demonstrated by FDG uptake in ischemic cells. This perfusion-metabolism mismatch is characteristic of myocardial hibernation and predictive of recovery after revascularization. 1 Segments with a matched decrease in perfusion and viability are representative of scar tissue. They were detected adjacent to hibernating segments but to a smaller extent, which is consistent with the findings that normal, stunned, hibernating, and scarred segments cohabit within the hibernating heart. 46 The minimal metabolic defects observed in the LAD territory may be explained by the variability in coronary anatomy and perfusion patterns of pigs, 47 partial-volume averaging effects at the apex attributable to reduced wall-thickness and increased motion compared with the adjacent heart walls, or may be a consequence of severely reduced blood flow as expected in territories most distal to the occlusion. Previous studies with the constrictor model reported hibernation with dobutamine stress echocardiography 32, 48, 49 or NOGA EMM, 50 but none has deliberately studied this model for hibernation. In this regard, we successfully created hibernation in our animals, accompanied by impaired wall motion, similar to what is also observed clinically.
Limitations of this study included the absence of a matrixonly group, motivated by animal economy and costs, because the purpose of this study was to (1) optimize the delivery of cells over the effects of cells alone and (2) use a preclinical setting with economy of treatment groups. Another limitation is that no angiography was performed to evaluate the occlusion status of the vessel at the time of cell injection; however, closure was histologically documented in all animals. Given this limitation and assuming random distribution among animals, the observation that the cells+matrix group was superior to the other treatments could be an underestimation of its true potential to restore perfusion and function to the heart. Finally, although the study analyzed multiple measures, we did not correct for repeated testing to avoid reducing statistical power, also affected by small sample sizes; for this reason, it is possible that type I (repeat testing) as well as type II (small sample size) errors may have occurred.
Conclusions
Within the aforementioned limitations, this study demonstrated the successful development of myocardial hibernation using a well-established ameroid constrictor model of chronic ischemia. This study was also the first to demonstrate that delivering CACs within a collagen matrix can improve MBF, reduce the extent of hibernation, and reduce wall motion abnormalities to a greater extent than cells alone. These results, obtained in a preclinical model and in a blinded fashion, constitute an important step toward the application of collagen matrices to support cell therapy and treat myocardial hibernation in the clinical setting.
